AstraZeneca

Member of UN Global Compact

Headquarters in United Kingdom

AstraZeneca website

Response rate: 100%

(click here for an explanation)

🔎 Run a search for “AstraZeneca”

Get RSS feed of these results

All stories

Article
3 May 2005

Paraquat ban debate re-ignites in Malaysian parliament

Author: James Rose, Ethical Corporation

Lobbyists look to have succeeded in overturning a ban on the use of the chemical paraquat as the Malaysian parliament looks set to revoke laws against its use, prompting conservationists and human rights activists to consider their campaign options. ...

Read more

Story
1 May 2005

Steps companies can take to manage impact of HIV/AIDS in Brazil, Russia, India, China

See full story

Article
1 May 2005

[PDF] full report: "HIV/AIDS Beyond Africa: Managing the Financial Impacts"

Author: F&C Asset Management & UBS

[refers to Anglo American, AngloGold Ashanti, AstraZeneca, AVI Group, BMW, BP, Chevron, Colgate-Palmolive, DaimlerChrysler, Dell, GlaxoSmithKline, Heineken, IBM, JD Group, Lafarge, Lonmin, Merck, Nedcor (now Nedbank), Procter & Gamble, Standard...

Read more

Article
27 April 2005

[PDF] Neglected diseases gets shot in arm

Author: Andrew Jack, Financial Times

While neglected diseases such as malaria and tuberculosis infect millions of people every year and kill hundreds of thousands, their concentration in low-income countries that have little ability to pay means the drugs industry has long turned its...

Read more

Article
30 March 2005

Renewed Commitment to Government – Industry Partnership to Improve Access to Medicines

Author: UK Department for International Development (DFID)

The UK Government and the world’s largest pharmaceutical companies today committed to continue to work together to help increase access to essential medicines for the world’s poorest countries...The UK Government’s framework for good practice has been...

Read more

Story
1 March 2005

GlaxoSmithKline, AstraZeneca, Merck, Pfizer & other firms join UK govt. in committing to increased access to essential medicines for poorest countries, including via differential pricing

See full story

Article
1 March 2005

[PDF] Increasing people’s access to essential medicines in developing countries: a framework for good practice in the pharmaceutical industry

Author: UK Department for International Development (DFID)

Responsibility for increasing access to essential medicines rests with the whole international community...In this context there is a particular role for pharmaceutical companies. As the producers of existing, and developers of new, medicines they can...

Read more

Article
31 December 2004

[PDF] Business and Economic Development: Pharmaceutical Sector Report

Author: AccountAbility & Business for Social Responsibility

[refers to Merck, Novo Nordisk, Aspen Pharmacare, Grunenthal, Novartis, Citadel Aurobindo Biotech & Citadel Fine Pharmaceuticals (both part of Aurobindo Pharmaceuticals), Abbott Laboratories, Bristol Myers-Squibb, Pfizer, Schering-Plough, Eli...

Read more

Article
30 December 2004
+ Español - Hide

Author: Expansion.com

Numerosas empresas europeas se han volcado con los damnificados por el debastador terremoto que ha asolado el sureste asiático cobrandose la vida de más de 120.000 personas y han anunciado millionarias donanciones para los países afectados. [se refiere...

Read more

Article
20 December 2004

Pharmaceutical company CEO comments on corporate responsibility

Author: Pharma Business Week

...Tom McKillop, CEO, AstraZeneca, said, "...[in the case of] medicines for AIDS or TB...partnerships involving governments, international aid agencies and companies offer the best chance of advancing healthcare in the poorest parts of the world."

Read more